Full Press Release Details
Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
YORK, April 04, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology
company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced pre-clinical data on the
effects of intranasal anti-CD3 monoclonal antibody in a model of intracerebral hemorrhage (hemorrhagic stroke) demonstrating a behavioral
outcome improvement at one month.
than 10% of people who have hemorrhagic stroke completely recover, and most are left with a disability that could include lasting effects
on their speech and physical function. Intranasal anti-CD3 monoclonal antibody showed improved motor and cognitive outcomes at one-month
post-intracerebral hemorrhage which is very exciting." commented Gabriele Cerrone, Executive Chairman and interim Chief Executive
Officer of Tiziana. "We are actively exploring the clinical development pathway in intracerebral hemorrhage using intranasal foralumab,
the first-ever fully human anti-CD3 monoclonal antibody in patients suffering from a hemorrhagic stroke. This new exciting finding further
validates our decision to focus on the clinical development of our lead asset, intranasal foralumab. This potential immunomodulatory
therapy represents a novel avenue for treatment of inflammatory diseases1"
T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds
to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation
by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development
have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's
lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical
response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several
applications pending and is expected to allow for broad pipeline applications.
Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC